Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 95 clinical trials
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera

The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a

hydroxyurea
ruxolitinib
interferon
  • 0 views
  • 24 Jan, 2021
  • 2 locations
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of

  • 182 views
  • 04 Jul, 2021
  • 84 locations
Ruxolitinib Combined With Dexamethasone for HLH

A protocol named as "HLH-DR" for patients with refractory and secondary hemophagocytic lymphohistiocytosismay.

  • 1 views
  • 22 Jan, 2021
Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation

Increasing experience of Ruxolitinib pre-allo SCT and data concerning Ruxolitinib during transplantation Diagnosis MF(includ Post-ET,Post-PV,PMF) With at least two month

  • 0 views
  • 12 Sep, 2021
  • 1 location
Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

This research study is evaluating the safety and efficacy of a topical drug treatment "Ruxolitinib" in treating Necrobiosis Lipoidica (NL).

  • 0 views
  • 26 Jan, 2021
  • 1 location
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

This study is a multi-site Phase Ib/II, 2-arm non-randomized clinical trial to determine the efficacy and tolerability of a response-adapted regimen combining ruxolitinib, dexamethasone, and

  • 0 views
  • 08 Aug, 2021
  • 2 locations
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD

Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation. The recognized first-line treatment for grade 3-4 aGVHD is systemic glucocorticoid. However, there is no recognized second-line treatment for grade 3-4 steroid-resistant aGVHD (SR-aGVHD). The investigators try to observe the efficacy and safety of …

  • 0 views
  • 02 Sep, 2021
  • 1 location
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic myeloid leukemia

  • 38 views
  • 11 May, 2021
  • 442 locations
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.

  • 1 views
  • 24 Jan, 2021
  • 2 locations
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Therapy of severe intestinal graft-versus-host disease (GVHD) despite the introduction of novel target agents is associated with worse outcome compared to the other forms. Response to steroids is observed only in about 10% of patients. The most promising approaches are JAK inhibition and fecal microbiota transplantation. In this pilot study …

  • 0 views
  • 25 Mar, 2021
  • 1 location